Candid Therapeutics Stock
HealthTechLooking to sell Candid Therapeutics stock or options?
Candid Therapeutics, a pioneer in biotechnology research, focuses on developing novel, easy-to-administer therapies for autoimmune diseases. The company specializes in advanced T-cell engager antibodies that precisely redirect T-cells to selectively eliminate autoreactive B-cells. This targeted approach enables patients with autoimmune diseases to achieve transformative efficacy and improved therapeutic outcomes.
Two River Group, Redmile Group, Soleus Capital, Polaris Innovation Fund, Foresite Capital, Minetta Brook Capital, TCG Crossover Management, Third Rock Ventures, Qiming Venture Partners, Boxer Capital, LifeSci Venture Partners, venBio, Venrock, Fairmount Partners, Fidelity Management & Research, OrbiMed, Vida Ventures (Boston), Qiming Venture Partners USA, Samsara BioCapital, Mirae Asset Capital Life Science, Franklin Templeton.